Advances and Challenges in Pharmaceutical Technology: Materials, Process Development and Drug Delivery Strategies examines recent advancements in pharmaceutical technology. The book discusses common formulation strategies, including the use of tools for statistical formulation optimization, Quality by design (QbD), process analytical technology, and the uses of various pharmaceutical biomaterials, including natural polymers, synthetic polymers, modified natural polymers, bioceramics, and other bioinorganics. In addition, the book covers rapid advancements in the field by providing a thorough understanding of pharmaceutical processes, formulation developments, explorations, and exploitation of various pharmaceutical biomaterials to formulate pharmaceutical dosage forms.

"How do you market a successful brand in today's constantly changing healthcare industry? Markus Saba and Hilary Gentile have spent decades confronting that challenge. In Brand Plan Rx, they show us how to use a simple and powerful framework of inspirational storytelling." -Arianna Huffington, founder and CEO, Thrive Global Build a healthcare brand that changes lives. A thriving brand requires a plan. Even the best marketing ideas cannot come to fruition without a cohesive brand plan. This is especially relevant and challenging in the health and wellness industry. Brand Plan Rx provides a proven road map that empowers you to make the choices that drive demand and will get you to synthesize your plan onto one page designed specifically with the health and wellness industry in mind. In Brand Plan Rx, healthcare and pharmaceutical marketing executives, professor Markus Saba and marketer Hilary Gentile, provide a step-by-step formula to uncover the unique needs that drive brand choice in the health and wellness industry. Drawing on their decades of work in launching major pharmaceutical and wellness brands, they outline exactly how you can create a strong, effective brand plan to launch and market your brand. Brand Plan Rx's Choice Map guides you through the difficult decisions that will build your brand. You will bring it all together into a cohesive and clear brand story. As you master synthesis and clarity, you will create a one-page Cohesion Map, a clear roadmap to use as your sounding board for all decisions you make for your brand. Ultimately, you'll learn how to apply traditional marketing principles to the healthcare space so that your brand will make a marked difference in people's lives. "Captures the essence of brand planning in the pharma/biotech space in a manner that is clear, simple, and practical." -Enrique Conterno, CEO, FibroGen, Inc. "A book that considers all the distinct factors of marketing in the healthcare industry. Practical, to the point, entertaining, and educational." -Rolf Hoffmann, chairman of the board of directors, Biotest "I recommend this book to all commercial leaders in our industry." -Burcu Eryilmaz, VP, Sanofi Genzyme "An essential guide from industry experts who have spearheaded thousands of successful launches." -Danielle Kayembe, founder and CEO, GreyFire Impact

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials. The author suggests that CMC (chemistry manufacturing controls) drug development must reset the line of sight - from supply of drug to the clinic and gaining a registration, to the building of a patient value stream. Capable processes and suppliers, streamlined logistics, flexible plant and equipment, shorter cycle times, effective flow of information and reduced waste. All these factors can and should be addressed at the CMC development stage.

"The public health of the developing world is the single issue of greatest significance for humanity over the next half century. This important book offers thoughtful analysis and practical ideas for confronting and addressing this issue through research and development of lifesaving vaccines."--Lawrence H. Summers, President, Harvard University

"Michael Kremer and Rachel Glennerster have produced a work of outstanding importance to the well-being of developing countries. "There are five billion people in the poor world, many suffering from debilitating or fatal diseases. The potential gains in overcoming this human suffering from the development of effective and cost-efficient vaccines are enormous. Yet the economic purchasing power of the rich world favors the development of vaccines and drugs for the rich world. "Strong Medicine" presents workable incentives for research and development to respond more powerfully to the human needs of poor people. Kremer and Glennerster have produced results that deserve the attention of all those who work in development and that chart a way forward for one of the greatest issues of our time."--Nicholas Stern, Second Permanent Secretary at HM Treasury in the United Kingdom, Visiting Professor at the London School of Economics, and former Chief Economist of the World Bank

""Strong Medicine" is full of insights that can make a real difference to the morbid world in which we live. It combines powerful analytical reasoning with practical insights and empirical knowledge to explore a highly promising way of expanding incentives for medicinal research. The possibility of making a significant difference through a commitment to purchase effectivevaccines as and when they are developed is thoroughly scrutinized in this definitive investigation, for which we have reason to be grateful."--Amartya Sen, Harvard University, Nobel Laureate in Economic Sciences

"This important book, on how to design markets for drugs to treat millions of diseased people in the developing world, has the added advantage of being an interesting read. The authors convey very well the intellectual excitement associated today with putting mechanism design into practice. They take the reader, one step at a time, through the various levels at which problems might arise and then show how the design is meant to take care of these problems."--Abhijit Banerjee, Massachusetts Institute of Technology

"Michael Kremer is likely the most thoughtful advocate of an exciting new approach for tackling the scourges of AIDS, malaria, and other diseases that primarily afflict the populations of less developed countries. In this book, he and Rachel Glennerster offer by far the most complete discussion I have seen of why this approach--one that would see authorities stimulate private efforts to develop medical treatment by providing a guaranteed market for them--should be adopted, and of how to deal with problems of implementation and design."--Kenneth Sokoloff, University of California, Los Angeles

Pharmacognosy: Current Herbal Medications and Natural Product Chemistry for a PharmD Curriculum focuses on the regulation and practicum of herbal medications in the real world. By introducing natural products as lead compounds for drug design, discovery, and development, the text bridges the gap between traditional herbal medications and current Western medicines. The book covers the unique and rich history of pharmacognosy in pharmacy practice and the critical role it has and continues to play in the evolution of modern Western medicine. Part I contains readings that provide students with an overview of the history of pharmacognosy, as well as the contemporary use of herbal medicine around the globe. In Part II, students learn about dietary supplements, botanical ingredients, herbal bioavailability, pharmacokinetics, and the mechanisms of herb-drug interactions. Part III covers natural products that can be used for pain management, anxiety and insomnia treatment, immune modulation, treating inflammation, infectious diseases, cancer, and more. The final part features case studies to demonstrate the practical applications of pharmacognosy. Featuring contemporary research and information that satisfies Accreditation Council for Pharmacy Education (ACPE) Standards, Pharmacognosy is ideal for courses and programs in pharmacy and medicinal chemistry.

Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis.

Drug Safety in Developing Countries: Achievements and Challenges provides comprehensive information on drug safety issues in developing countries. Drug safety practice in developing countries varies substantially from country to country. This can lead to a rise in adverse reactions and a lack of reporting can exasperate the situation and lead to negative medical outcomes. This book documents the history and development of drug safety systems, pharmacovigilance centers and activities in developing countries, describing their current situation and achievements of drug safety practice. Further, using extensive case studies, the book addresses the challenges of drug safety in developing countries.

Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant